The National Institutes of Health through the Rare Diseases Clinical Research Consortia has awarded a research team from Yale University, George Washington University, and Duke University $7.8 million to establish a rare disease network for myasthenia gravis.
- September 26, 2017
“Mom?” the middle-aged man asked. He recognized the voice, but the words were muffled and strange. I’ll be right over, he said into the phone. The 15-minute drive from his small Connecticut town to his mother’s seemed to last forever. Had she had a stroke? She was 94, and though she’d always been healthy, at her age, anything could happen.
- September 07, 2017
A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab, commonly used to treat the incurable autoimmune disease marked by muscle weakness and fatigue.
- June 13, 2017
Every two weeks, Ed Czaczkes comes to the Yale Center for Clinical Investigation Hospital Research Unit on a 10th floor at Yale New Haven Hospital. He is getting treated for Myasthenia Gravis or MG.
- March 25, 2017
Bull’s Eye: Targeted Immunotherapy of Myasthenia Gravis
- April 25, 2016
BeatMG: B Cell Targeted Treatment in Myasthenia Gravis, A Phase II Trial of Rituximab in MG study achieves enrollment goal!
- February 03, 2015
Myasthenia gravis (MG) is a chronic, autoimmune, neurological disease that affects about 75,000 people in the United States. At Yale Dr. Richard Nowak is leading a clinical trial to test whether the medication, rituximab, may help patients with MG decrease their prednisone dosage or even discontinue it.
- October 16, 2013
Rituximab in Myasthenia Gravis
- April 14, 2010
AAN: Rituximab Effective in Myasthenia Gravis By John Gever, Senior Editor, MedPage Today Follow Link to Article.